A High-throughput Method to Detect RNA Profiling by Integration of RT-MLPA with Next Generation Sequencing Technology
Overview
Affiliations
RNA in formalin-fixed and paraffin-embedded (FFPE) tissues provides large amount of information indicating disease stages, histological tumor types and grades, as well as clinical outcomes. However, Detection of RNA expression levels in formalin-fixed and paraffin-embedded samples is extremely difficult due to poor RNA quality. Here we developed a high-throughput method, Reverse Transcription-Multiple Ligation-dependent Probe Sequencing (RT-MLPSeq), to determine expression levels of multiple transcripts in FFPE samples. By combining Reverse Transcription-Multiple Ligation-dependent Amplification method and next generation sequencing technology, RT-MLPSeq overcomes the limit of probe length in multiplex ligation-dependent probe amplification assay and thus could detect expression levels of transcripts without quantitative limitations. We proved that different RT-MLPSeq probes targeting on the same transcripts have highly consistent results and the starting RNA/cDNA input could be as little as 1 ng. RT-MLPSeq also presented consistent relative RNA levels of selected 13 genes with reverse transcription quantitative PCR. Finally, we demonstrated the application of the new RT-MLPSeq method by measuring the mRNA expression levels of 21 genes which can be used for accurate calculation of the breast cancer recurrence score - an index that has been widely used for managing breast cancer patients.
Li J, Chi J, Yang Y, Song Z, Yang Y, Zhou X Cell Regen. 2023; 12(1):22.
PMID: 37264282 PMC: 10235360. DOI: 10.1186/s13619-023-00164-9.
Disequilibrium between and Circular and Messenger RNAs Plays a Role in Breast Cancer.
Levacher C, Viennot M, Drouet A, Beaussire L, Coutant S, Thery J Cancers (Basel). 2023; 15(7).
PMID: 37046838 PMC: 10093293. DOI: 10.3390/cancers15072176.
Analysis of differential gene expression profile identifies novel biomarkers for breast cancer.
Pan Y, Liu G, Yuan Y, Zhao J, Yang Y, Li Y Oncotarget. 2018; 8(70):114613-114625.
PMID: 29383106 PMC: 5777718. DOI: 10.18632/oncotarget.23061.